Where are we on worms?

被引:42
|
作者
Elliott, David E. [1 ,2 ]
Weinstock, Joel V. [3 ]
机构
[1] Univ Iowa, Dept Internal Med, Carver Coll Med, Div Gastroenterol, Iowa City, IA 52242 USA
[2] VAMC, Iowa City, IA USA
[3] Tufts Med Ctr, Div Gastroenterol, Boston, MA USA
关键词
colitis; helminths; inflammatory bowel disease; intestinal inflammation; mucosa; INFLAMMATORY-BOWEL-DISEASE; HELIGMOSOMOIDES-POLYGYRUS INFECTION; CHEMICALLY-INDUCED COLITIS; TRICHURIS-SUIS THERAPY; CROHNS-DISEASE; INTESTINAL PARASITES; NECATOR-AMERICANUS; ULCERATIVE-COLITIS; EPIDEMIOLOGY; PREVALENCE;
D O I
10.1097/MOG.0b013e3283572f73
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose of review There is something about living in an industrialized country that dramatically increases the risk of acquiring inflammatory bowel disease (IBD). Loss of routine exposure to parasitic worms (helminths), due to modern highly hygienic life styles, likely contributes to this risk. This article reviews current understanding on how helminths influence intestinal inflammation and mucosal immune responses. Recent findings IBD emerges in populations as regions develop socioeconomically and lose exposure to previously ubiquitous helminthic infections. Helminthic infections provided strong selective pressure for the dissemination of gene variants, many of which predispose to development of IBD. In animal models of IBD, helminth colonization suppresses intestinal inflammation through multiple mechanisms including induction of innate and adaptive regulatory circuits. Trials using helminths like hookworm (Necator americanus) or porcine whipworm (Trichuris suis) show that they are safe and may be effective therapies for the control of the aberrant intestinal inflammation seen in Crohn's disease and ulcerative colitis. Summary Evidence is accumulating that highly hygienic living conditions create risk for developing immune-mediated disease such as IBD. To live in their host, helminths have developed the ability to activate cells of innate and adaptive immunity that suppress inflammation. Therapeutic trials using helminths are in progress.
引用
收藏
页码:551 / 556
页数:6
相关论文
共 50 条
  • [1] Do We Need Worms to Promote Immune Health?
    Weinstock, Joel V.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2015, 49 (02) : 227 - 231
  • [2] Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
    Park, Sang Hyoung
    INTESTINAL RESEARCH, 2022, 20 (02) : 159 - 164
  • [3] Artificial Intelligence and IBD: Where are We Now and Where Will We Be in the Future?
    Ahmed M.
    Stone M.L.
    Stidham R.W.
    Current Gastroenterology Reports, 2024, 26 (5) : 137 - 144
  • [4] The Future of IBD Therapy: Where Are We and Where Should We Go Next?
    Mao, Ren
    Hu, Pin-Jin
    DIGESTIVE DISEASES, 2016, 34 (1-2) : 175 - 179
  • [5] ETIOLOGY OF INFLAMMATORY BOWEL DISEASES - WHERE HAVE WE BEEN - WHERE ARE WE GOING
    GITNICK, G
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1990, 25 : 93 - 96
  • [6] Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
    Hasenoehrl, Carina
    Storr, Martin
    Schicho, Rudolf
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (04) : 329 - 337
  • [7] Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
    Naseer, Maliha
    Poola, Shiva
    Ali, Syed
    Samiullah, Sami
    Tahan, Veysel
    CURRENT CLINICAL PHARMACOLOGY, 2020, 15 (03): : 216 - 233
  • [8] Treatment of IBD: Where We Are and Where We Are Going
    Bernstein, Charles N.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (01) : 114 - 126
  • [9] Of worms, mice and man: An overview of experimental and clinical helminth-based therapy for inflammatory bowel disease
    Heylen, Marthe
    Ruyssers, Nathalie E.
    Gielis, Els M.
    Vanhomwegen, Els
    Pelckmans, Paul A.
    Moreels, Tom G.
    De Man, Joris G.
    De Winter, Benedicte Y.
    PHARMACOLOGY & THERAPEUTICS, 2014, 143 (02) : 153 - 167
  • [10] Management of ulcerative colitis: where are we at and where are we heading?
    Abbas, Adnan
    Di Fonzo, David M. P.
    Wetwittayakhlang, Panu
    Al-Jabri, Reem
    Lakatos, Peter L.
    Bessissow, Talat
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (10) : 567 - 574